Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.1.02104
European Journal of Endocrinology, Vol 154, Issue 3, 367-372
Copyright © 2006 by European Society of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bohbot, N. L.
Right arrow Articles by Delemer, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bohbot, N. L.
Right arrow Articles by Delemer, B.
CLINICAL STUDY

Interferon-{alpha}-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves’ disease

Nathalie Lévy Bohbot1, Jacques Young3, Jacques Orgiazzi5, Catherine Buffet4, Maud François1, Brigitte Bernard-Chabert2, Céline Lukas-Croisier1 and Brigitte Delemer1

1 Service d’Endocrinologie and 2 Service de Gastro-Entéro-Hepatologie, Centre Hospitalier Universitaire de Reims, Hôpital Robert Debré, avenue du Général Koenig, 51092 Reims, Cedex, France, 3 Service d’Endocrinologie and 4 Service d’Hépato-Gastro-Entérologie, Assistance Publique, Hôpitaux de Paris, Centre Hospitalier Universitaire de Bicêtre, France and 5 Service d’Endocrinologie-Diabète-Maladies Métaboliques, Centre Hospitalier Universitaire Lyon Sud, Pierre-Bénite, France

(Correspondence should be addressed to B Delemer; Email: bdelemer{at}chureims.fr)

Autoimmune thyroid disease is a common side-effect of interferon-{alpha} (IFN-{alpha}) treatment of viral hepatitis C. We have described three patients with hepatitis C for whom IFN-{alpha} and ribavirin were prescribed and who developed two successive phases of silent thyroiditis followed by hyperthryroidism relapse due to Graves’ disease. These three men had no known history of familial or personal thyroid disease. Destructive thyrotoxicosis appeared 4–6 months after starting IFN-{alpha}, followed by Graves’ hyperthyroidism within 8 to11 months. The thyrotropin (TSH) level was normal before IFN-{alpha} was started. The diagnosis of destructive thyroiditis was confirmed by anti-TSH receptor antibody (TSHRAb) negativity and the absence of radionuclide (123I or 99Tc) uptake on thyroid scintiscans. Eight to eleven months after starting treatment, TSHRAb positivity and intense scintigraphic uptake confirmed the appearance of Graves’ disease. IFN-{alpha} was continued in only one patient. Hence, hyperthyroidism induced by IFN-{alpha} could correspond to the first phase of silent thyroiditis, to Graves’ disease or to the succession of both. Rigorous diagnostic procedures with repeated scintiscans and TSHRAb titering are necessary to avoid a false diagnosis and inappropriate therapy.




This article has been cited by other articles:


Home page
 QJMHome page
H.A. Tran, G.E.M. Reeves, and T.L. Jones
The natural history of interferon-{alpha}2b-induced thyroiditis and its exclusivity in a cohort of patients with chronic hepatitis C infection
QJM, February 1, 2009; 102(2): 117 - 122.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
E. S. Mittra, R. D. Niederkohr, C. Rodriguez, T. El-Maghraby, and I. R. McDougall
Uncommon Causes of Thyrotoxicosis
J. Nucl. Med., February 1, 2008; 49(2): 265 - 278.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 European Society of Endocrinology.